Investor Presentaiton

Investor presentation Full year 2018 Slide 10 SaxendaⓇ sales increased by 60% in 2018 and continues to gain market share in the global anti-obesity market Solid SaxendaⓇ sales growth since launch DKK million North America Operations International Operations 1,400 1,200 Annual growth 2016-2018: ~35% 1,000 800 600 400 200 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2016 2018 • Continued global roll-out of SaxendaⓇ Novo Nordisk is the value market leader in the global anti- obesity market with 45% market share. Value market share in North America Operations is 65.5% and in International Operations 32.5% SaxendaⓇ sales grew by 60% in 2018 measured in local currencies driven by both North America Operations (sales growth of 39%) and International Operations (sales growth of 131%) • SaxendaⓇ is now launched in North America and in 39 countries in four regions in International Operations Continued efforts focusing on expanding the obesity segment. Novo Nordisk invests in progressing its innovative obesity pipeline and market development activities such as patient support and educator programmes Source: IQVIA monthly from Nov 2018 Note: Numbers in the graph are reported quarterly sales changing obesity

View entire presentation